Home Imprint Sitemap Newsletter Sign in to our Service-Newsletter Meet us at... World ADC Summit 2014 Antibody-Drug Conjugates Based on RNA-Polymerase II Inhibiting Payloads October 26-29, 2014 San Diego, CA, USA Speaker: J. Anderl - Oct 26, 2014, 03:00 p.m. PEGS Europe 2014 Analytical Characterisation of the RNA-Polymerase II inhibitor Amanitin and Amanitin-Based ADCs November 3-7, 2014 Lisbon, Portugal Speaker: A. Pahl - Nov 6, 2014, 04:15 p.m. Heidelberg Pharma GmbH is a company providing pre-clinical drug discovery and development services. Services include explorative pharmacology in the field of cancer, autoimmunity and inflammation, hand-in-hand with bioanalytical methods. Our performance for our clients is characterized by a high degree of flexibility, rapid turn-around and consistent high quality. Heidelberg Pharma's own R&D flagship is its proprietary 2nd generation ADC technology for more effective anti-cancer drugs. News & Events: January 2014 Heidelberg Pharma is very pleased to invite you to a Taconic Webinar on »Human TNF-α Transgenic Mouse Model of Spontaneous Arthritis« presented by our CSO, Andreas Pahl [...] About us Profile News & Events Management History Contact us Google+ Services General Cancer Inflammation DMPK Molecular biology Quality assurance ADC Technology Technology References Bibliography Investor Investor contact Contact Business Development Service Jobs Directions Unsubscribe from our Service-Newsletter